Amicus Therapeutics (FOLD), Glaxo (GSK) Report Study 011 Did Not Achieve Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Wedbush Downgrades Amicus Therapeutics (FOLD) to Underperform, Sees Another 50% Slide
December 21, 2012 9:39 AM ESTAmicus Therapeutics (NASDAQ: FOLD) fell 47 percent on Thursday after its ongoing migalastat monotherapy Phase III trial did not meet the primary and a pre-defined secondary endpoint, however, one analyst thinks it goes down another 50 percent from here.
Wedbush downgraded Amicus from Neutral to... More
Leerink Swann Cuts PT on Amicus Therapeutics (FOLD), But Remains Overall Bullilsh
December 20, 2012 12:25 PM ESTLeerink Swann cut its price target on Amicus Therapeutics (NASDAQ: FOLD) from $9 to $5 after the company reported Wednesday that Phase III study ('011) of Amigal monotherapy in Fabry disease missed its primary and secondary endpoints. However, they maintained an Outperform rating.... More
Amicus (FOLD) Slammed Following Study 011 Update
December 19, 2012 4:36 PM ESTAmicus Therapeutics (Nasdaq: FOLD) shares are getting slammed in late trading following an update on Study 011. Amicus said the study missed its primary endpoint.
Shares are down about 50 percent on resumption.... More
Amicus Therapeutics (FOLD) to resume trading at 4:30PM ET
December 19, 2012 4:27 PM ESTAmicus Therapeutics, Inc. (NASDAQ: FOLD) to resume trading at 4:30PM ET after reporting that a study failed to show statistical benefit.... More
Amicus Therapeutics (FOLD) halted, news pending
December 19, 2012 4:00 PM ESTAmicus Therapeutics, Inc. (NASDAQ: FOLD) halted, news pending... More
